Skip to main content
. 2022 Jun 28;10(7):1531. doi: 10.3390/biomedicines10071531

Figure 2.

Figure 2

USP6NL is highly expressed in temozolomide (TMZ)-resistant GBM (U87MG-R and T98G-R) cells. (A) Representative image of Western blot analysis showing the USP6NL expression in TMZ-resistant GBM cells. (B) Viability assay performed using the CCK-8 assay kit showing that established TMZ-resistant cell lines, U87MG-R and U251-R, exhibited increased resilience toward TMZ treatment. (C) shRNA (shUSP6NL) knockdown of USP6NL. Western blot analysis demonstrated that the expression of USP6NL and EGFR was significantly reduced in the knockdown cells compared with the control. (D,E) Reduction in the cell viability and change in the morphology of TMZ-resistant GBM cells, demonstrating the effect of USP6NL-knockdown sensitized resistant cells toward TMZ. (F) Bar graph shows the representative proportion of apoptotic cells according to flow cytometry of Annexin V-FITC/PI staining in USP6NL-knockdown and control TMZ-resistant cells treated with TMZ. ** p < 0.01 and *** p < 0.001.